NEW YORK, Nov. 5, 2021 /PRNewswire/ — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) the “Company”), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce the appointment of Maria A. Oquendo, M.D., Ph.D. to its Scientific Advisory Board. Dr. Oquendo is Ruth Meltzer Professor and Chairman of Psychiatry at University of Pennsylvania and…


Previous articlePT270 – Dr. Rachel Yehuda – Research Trials and The Future of Psychedelic Neuroscience
Next articlePharmaDrug Advances Psychedelics Program with Analogue DMT Formulations to Treat Eye Diseases